The evidence, honestly
What the research actually shows.
A plain-language summary of the published science on regenerative approaches for joint pain — where the evidence is strong, where it is still early, and what none of it establishes yet.
Regenerative wellness is one of the most actively studied areas in musculoskeletal medicine — and one of the most over-marketed. This page is our attempt to describe the research the way a careful reader would: attributing findings to the studies that produced them, distinguishing strong evidence from early evidence, and being clear about what remains unknown.
How to read this page. Everything below describes what researchers have published about approaches in this field in general. It is educational, not medical advice, and none of it is a claim about any specific product or a promise of any result. Different providers offer different approaches — it’s always worth asking which one, and why.
Mechanism
How the body’s repair systems are thought to work.
Your body maintains its own structural-support and repair systems — the framework that holds tissue together and the signaling that helps it maintain itself. Much of the research in this field studies how those systems function and how carefully sourced human tissue products relate to them. This is foundational science: it explains what researchers are investigating, not what any product has been shown to do.
Reviews of the underlying biology of orthobiologics and tissue-signaling appear across the musculoskeletal literature (see selected sources below).
Where the evidence is strongest
Platelet-rich plasma (PRP).
The most-studied approach — made from your own blood.
Platelet-rich plasma is prepared by concentrating the platelets from a sample of a person’s own blood. Because it is autologous, it has been studied more than any other regenerative approach.
A 2025 Level-1 meta-analysis in the American Journal of Sports Medicine reported statistically significant, clinically meaningful improvements in pain and function versus placebo in knee osteoarthritis out to 12 months. Other 2025 reviews reach broadly similar conclusions while rating the overall certainty of evidence as “moderate” and noting that results are not uniform — some placebo-controlled trials show no lasting benefit.
Note: PRP is one approach in this field, and is different from the human tissue-allograft products discussed at Renvi events. Strong evidence for one approach is not evidence for another.
Where the evidence is still early
Tissue allografts and other approaches.
Amniotic and umbilical (Wharton’s jelly) allografts.
Published human research on tissue allografts for knee osteoarthritis is limited and preliminary. A 2025 systematic review of amniotic suspension allografts describes early positive signals alongside a small number of studies and a clear call for more high-quality trials. Human evidence specific to umbilical (Wharton’s jelly) allografts is earlier still. All of this should be read as an emerging area of study — not as an established or proven treatment.
Bone marrow aspirate concentrate (BMAC).
BMAC is drawn from a person’s own bone marrow. Systematic reviews generally find it has a favorable safety profile, with efficacy signals that are mixed and still under investigation rather than settled by consensus.
The field is under active study
Research in progress.
One honest sign of a legitimate field is that it is being tested in rigorous, ongoing clinical trials. A few examples currently registered on the U.S. National Library of Medicine’s ClinicalTrials.gov:
- NCT05517434 — a placebo-controlled trial of bone-marrow and platelet preparations for knee osteoarthritis.
- NCT06608134 — an early safety study of an umbilical-cord (Wharton’s jelly) allograft injection for the knee.
- NCT05985785 — a randomized trial comparing bone marrow concentrate with corticosteroid for knee osteoarthritis.
- NCT05727371 — a multicenter, double-blind trial of a platelet preparation for moderate-to-severe knee osteoarthritis.
Registration of a trial means a question is being studied — not that an answer has been reached.
Before you consider anything
Ask good questions first.
A short list of questions protects you in this category — where the tissue comes from, whether there’s a Certificate of Analysis, what the published research actually shows, and whether a licensed physician oversees the clinical side. Read the questions worth asking →
The bottom line
Published research suggests possibilities that researchers are actively studying. For one approach — PRP — the evidence in the knee is relatively strong; for tissue allografts it is early and preliminary. None of it establishes any product as a proven treatment, and no regenerative tissue product is FDA-approved to treat, cure, or prevent osteoarthritis or any other disease.
That is exactly why we lead with education. The right next step is a private conversation with an independently licensed provider — ideally alongside your own doctor. The decision always belongs to you and that provider.
Selected published sources
These are examples of the peer-reviewed literature described above. They concern approaches in this field generally, not any specific Renvi product.
- Boffa A, et al. Platelet-rich plasma for knee osteoarthritis (Level-1 meta-analysis). American Journal of Sports Medicine, 2025. PubMed 39751394
- Glinkowski W, et al. PRP in knee osteoarthritis: a review (GRADE-moderate certainty). Journal of Clinical Medicine, 2025. PubMed 40507744
- Systematic review of platelet-rich plasma for tendinopathy. Orthopaedic Journal of Sports Medicine, 2024. PubMed 39611122
- Efficacy of amniotic suspension allografts in knee osteoarthritis (systematic review). Journal of Knee Surgery, 2025. PubMed 39793609
- Complication rates of bone marrow aspirate concentrate injections (systematic review). Journal of Orthopaedics, 2025. PubMed 39473874
Renvi Health is a management services organization. Clinical care, if any, is provided by independently licensed healthcare providers. The research summarized here concerns regenerative approaches in general and is not a claim about any specific product or outcome. Tissue products discussed at Renvi events are regulated as Section 361 HCT/Ps under 21 CFR Part 1271 and are not approved by the U.S. Food and Drug Administration to diagnose, treat, cure, mitigate, or prevent any disease, including osteoarthritis. Information on this page is educational and is not medical advice. Results vary and are not guaranteed. All decisions should be made with a licensed medical provider.